Endothelin blockade in diabetic kidney disease

Journal of Clinical Medicine

Volumn 4, Issue 6, 2015, Pages 1171-1192

  Anguiano, Lidia ^a   Riera, Marta ^a,b   Pascual, Julio ^a,b   Soler, María José ^a,b  

^a HOSPITAL DEL MAR   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Diabetic kidney disease (DKD); Endothelin A receptor (ETA receptor); Endothelin B receptor (ETB receptor); Endothelin receptor antagonists; Endothelin 1 (ET 1)

Indexed keywords

5 DIMETHYLAMINO N (3, 4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; ATRASENTAN; AVOSENTAN; BOSENTAN; BQ 238; BQ 778; BQ 928; CYCLO (DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; PLACEBO; SITAXSENTAN; TAK 044; UNCLASSIFIED DRUG;

DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG TARGETING; FOLLOW UP; GLOMERULUS; GLOMERULUS FILTRATION RATE; HUMAN; IATROGENIC DISEASE; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY TUBULE; MULTICENTER STUDY (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REVIEW; SIGNAL TRANSDUCTION; VASCULARIZATION; VASOCONSTRICTION;

EID: 84962609220     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm4061171     Document Type: Review

References (104)

1. KDOQI. Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am. J. Kidney Dis. 2012, 60, 850–886.
2. Hickey, K.A.; Rubanyi, G.; Paul, R.J.; Highsmith, R.F. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am. J. Physiol. 1985, 248, C550–C556.
3. Inoue, A.; Yanagisawa, M.; Kimura, S.; Kasuya, Y.; Miyauchi, T.; Goto, K.; Masaki, T. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. USA 1989, 86, 2863–2867.
4. Karet, F.E.; Davenport, A.P. Localization of endothelin peptides in human kidney. Kidney Int. 1996, 49, 382–387.
5. Morita, S.; Kitamura, K.; Yamamoto, Y.; Eto, T.; Osada, Y.; Sumiyoshi, A.; Koono, M.; Tanaka, K. Immunoreactive endothelin in human kidney. Ann. Clin. Biochem. 1991, 28, 267–271.
6. Kohan, D.E. Endothelins in the normal and diseased kidney. Am. J. Kidney Dis. 1997, 29, 2–26.
7. Kuc, R.; Davenport, A.P. Comparison of endothelin-A and endothelin-B receptor distribution visualized by radioligand binding versus immunocytochemical localization using subtype selective antisera. J. Cardiovasc. Pharmacol. 2004, 44, S224–S226.
8. Saleh, M.A.; Boesen, E.I.; Pollock, J.S.; Savin, V.J.; Pollock, D.M. Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. Hypertension 2010, 56, 942–949.
9. Elmarakby, A.A.; Loomis, E.D.; Pollock, J.S.; Pollock, D.M. NADPH oxidase inhibition attenuates oxidative stress but not hypertension produced by chronic ET-1. Hypertension 2005, 45, 283–287.
10. Kohan, D.E.; Barton, M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int. 2014, 86, 896–904.
11. Kohan, D.E.; Rossi, N.F.; Inscho, E.W.; Pollock, D.M. Regulation of blood pressure and salt homeostasis by endothelin. Physiol. Rev. 2011, 91, 1–77.
12. Barton, M. Reversal of proteinuric renal disease and the emerging role of endothelin. Nat. Clin. Pract. Nephrol. 2008, 4, 490–501.
13. Pernow, J.; Franco-Cereceda, A.; Matran, R.; Lundberg, J.M. Effect of endothelin-1 on regional vascular resistances in the pig. J. Cardiovasc. Pharmacol. 1989, 13, S205–S206.
14. Nambi, P.; Pullen, M.; Wu, H.L.; Aiyar, N.; Ohlstein, E.H.; Edwards, R.M. Identification of endothelin receptor subtypes in human renal cortex and medulla using subtype-selective ligands. Endocrinology 1992, 131, 1081–1086.
15. Furuya, S.; Naruse, S.; Nakayama, T.; Nokihara, K. Effect and distribution of intravenously injected 125I-endothelin-1 in rat kidney and lung examined by electron microscopic radioautography. Anat. Embryol. (Berl) 1992, 185, 87–96.
16. Frank, K.; Zeier, M.; Gross, M.L.; Waldherr, R.; Ritz, E.; Amann, K. Comprehensive immunohistological analysis of the endothelin system in human kidney grafts. Nephrol. Dial. Transplant. 2006, 21, 1365–1372.
17. Chen, X.; Berrou, J.; Nguyen, G.; Sraer, J.D.; Rondeau, E. Endothelin-1 induces rapid and long lasting internalization of the thrombin receptor in human glomerular epithelial cells. Biochem. Biophys. Res. Commun. 1995, 217, 445–451.
18. Yamamoto, T.; Hirohama, T.; Uemura, H. Endothelin B receptor-like immunoreactivity in podocytes of the rat kidney. Arch. Histol. Cytol. 2002, 65, 245–250.
19. Wendel, M.; Knels, L.; Kummer, W.; Koch, T. Distribution of endothelin receptor subtypes ETA and ETB in the rat kidney. J. Histochem. Cytochem. 2006, 54, 1193–1203.
20. Herman, W.H.; Emancipator, S.N.; Rhoten, R.L.; Simonson, M.S. Vascular and glomerular expression of endothelin-1 in normal human kidney. Am. J. Physiol. 1998, 275, F8–F17.
21. Orth, S.R.; Amann, K.; Gehlen, F.; Unger, L.; Wagner, J.; Raschack, M.; Ritz, E. Adult human mesangial cells (HMCs) express endothelin-B-receptors which mediate endothelin-1-induced cell growth. J. Cardiovasc. Pharmacol. 2000, 36, S232–S237.
22. Takemoto, F.; Uchida, S.; Ogata, E.; Kurokawa, K. Endothelin-1 and endothelin-3 binding to rat nephrons. Am. J. Physiol. 1993, 264, F827–F832.
23. Uchida, S.; Takemoto, F.; Ogata, E.; Kurokawa, K. Endothelin-1 and -3 binding to ETB receptors in rat renal tubules. J. Cardiovasc. Pharmacol. 1993, 22, S177–S180.
24. Terada, Y.; Tomita, K.; Nonoguchi, H.; Marumo, F. Different localization of two types of endothelin receptor mRNA in microdissected rat nephron segments using reverse transcription and polymerase chain reaction assay. J. Clin. Invest. 1992, 90, 107–112.
25. Yamamoto, T.; Uemura, H. Distribution of endothelin-B receptor-like immunoreactivity in rat brain, kidney, and pancreas. J. Cardiovasc. Pharmacol. 1998, 31, S207–S211.
26. Yamamoto, T.; Suzuki, H.; Kubo, Y.; Matsumoto, A.; Uemura, H. Endothelin A receptor-like immunoreactivity on the basal infoldings of rat renal tubules and collecting ducts. Arch. Histol. Cytol. 2008, 71, 77–87.
27. Moridaira, K.; Nodera, M.; Sato, G.; Yanagisawa, H. Detection of prepro-ET-1 mRNA in normal rat kidney by in situ RT-PCR. Nephron Exp. Nephrol. 2003, 95, e55–e61.
28. Bailey, M.A.; Haton, C.; Orea, V.; Sassard, J.; Bailly, C.; Unwin, R.J.; Imbert-Teboul, M. ETA receptor-mediated Ca2+ signaling in thin descending limbs of Henle’s loop: Impairment in genetic hypertension. Kidney Int. 2003, 63, 1276–1284.
29. Dean, R.; Zhuo, J.; Alcorn, D.; Casley, D.; Mendelsohn, F.A. Cellular distribution of 125I-endothelin-1 binding in rat kidney following in vivo labeling. Am. J. Physiol. 1994, 267, F845–F852.
30. Francis, B.N.; Abassi, Z.; Heyman, S.; Winaver, J.; Hoffman, A. Differential regulation of ET(A) and ET(B) in the renal tissue of rats with compensated and decompensated heart failure. J. Cardiovasc. Pharmacol. 2004, 44, S362–S365.
31. Ong, A.C.; Jowett, T.P.; Firth, J.D.; Burton, S.; Karet, F.E.; Fine, L.G. An endothelin-1 mediated autocrine growth loop involved in human renal tubular regeneration. Kidney Int. 1995, 48, 390–401.
32. Lundberg, J.M.; Ahlborg, G.; Hemsen, A.; Nisell, H.; Lunell, N.O.; Pernow, J.; Rudehill, A.; Weitzberg, E. Evidence for release of endothelin-1 in pigs and humans. J. Cardiovasc. Pharmacol. 1991, 17, S350–S353.
33. Backer, A.; Bokemeyer, D.; Kramer, H.J. Endothelin synthesis and receptors in porcine kidney. Acta Physiol. Scand. 2001, 171, 105–112.
34. Karet, F.E.; Kuc, R.E.; Davenport, A.P. Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney. Kidney Int. 1993, 44, 36–42.
35. Fligny, C.; Barton, M.; Tharaux, P.L. Endothelin and podocyte injury in chronic kidney disease. Contrib. Nephrol. 2011, 172, 120–138.
36. Morigi, M.; Buelli, S.; Angioletti, S.; Zanchi, C.; Longaretti, L.; Zoja, C.; Galbusera, M.; Gastoldi, S.; Mundel, P.; Remuzzi, G.; et al. In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: Implication for permselective dysfunction of chronic nephropathies. Am. J. Pathol. 2005, 166, 1309–1320.
37. Saleh, M.A.; Boesen, E.I.; Pollock, J.S.; Savin, V.J.; Pollock, D.M. Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes. Diabetologia 2011, 54, 979–988.
38. Sorokin, A.; Kohan, D.E. Physiology and pathology of endothelin-1 in renal mesangium. Am. J. Physiol. Renal Physiol. 2003, 285, F579–F589.
39. Badr, K.F.; Murray, J.J.; Breyer, M.D.; Takahashi, K.; Inagami, T.; Harris, R.C. Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney. Elucidation of signal transduction pathways. J. Clin. Invest. 1989, 83, 336–342.
40. Simonson, M.S.; Dunn, M.J. Endothelin-1 stimulates contraction of rat glomerular mesangial cells and potentiates beta-adrenergic-mediated cyclic adenosine monophosphate accumulation. J. Clin. Invest. 1990, 85, 790–797.
41. Yokokawa, K.; Kohno, M.; Johchi, M.; Horio, T.; Murakawa, K.; Yasunari, K.; Yanagisawa, M.; Takeda, T. Effect of endothelin receptor antagonist, BQ-123, on Ca2+ signaling in cultured rat mesangial cells. Life Sci. 1993, 53, 1631–1641.
42. Inscho, E.W.; Imig, J.D.; Cook, A.K.; Pollock, D.M. ETA and ETB receptors differentially modulate afferent and efferent arteriolar responses to endothelin. Br. J. Pharmacol. 2005, 146, 1019–1026.
43. Evans, R.G.; Madden, A.C.; Oliver, J.J.; Lewis, T.V. Effects of ET(A)- and ET(B)-receptor antagonists on regional kidney blood flow, and responses to intravenous endothelin-1, in anaesthetized rabbits. J. Hypertens. 2001, 19, 1789–1799.
44. Dhaun, N.; Ferro, C.J.; Davenport, A.P.; Haynes, W.G.; Goddard, J.; Webb, D.J. Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. Nephrol. Dial. Transplant. 2007, 22, 3228–3234.
45. Denton, K.M.; Shweta, A.; Finkelstein, L.; Flower, R.L.; Evans, R.G. Effect of endothelin-1 on regional kidney blood flow and renal arteriole calibre in rabbits. Clin. Exp. Pharmacol. Physiol. 2004, 31, 494–501.
46. Goddard, J.; Johnston, N.R.; Hand, M.F.; Cumming, A.D.; Rabelink, T.J.; Rankin, A.J.; Webb, D.J. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: A comparison of selective and combined endothelin receptor blockade. Circulation 2004, 109, 1186–1193.
47. Schildroth, J.; Rettig-Zimmermann, J.; Kalk, P.; Steege, A.; Fahling, M.; Sendeski, M.; Paliege, A.; Lai, E.Y.; Bachmann, S.; Persson, P.B.; et al. Endothelin type A and B receptors in the control of afferent and efferent arterioles in mice. Nephrol. Dial. Transplant. 2011, 26, 779–789.
48. Qiu, C.; Samsell, L.; Baylis, C. Actions of endogenous endothelin on glomerular hemodynamics in the rat. Am. J. Physiol. 1995, 269, R469–R473.
49. Yu, C.; Yang, Z.; Ren, H.; Zhang, Y.; Han, Y.; He, D.; Lu, Q.; Wang, X.; Yang, C.; Asico, L.D.; et al. D3 dopamine receptor regulation of ETB receptors in renal proximal tubule cells from WKY and SHRs. Am. J. Hypertens. 2009, 22, 877–883.
50. Liu, Y.; Yang, J.; Ren, H.; He, D.; Pascua, A.; Armando, M.I.; Yang, C.; Zhou, L.; Felder, R.A.; Jose, P.A.; et al. Inhibitory effect of ETB receptor on Na(+)-K(+) ATPase activity by extracellular Ca(2+) entry and Ca(2+) release from the endoplasmic reticulum in renal proximal tubule cells. Hypertens. Res. 2009, 32, 846–852.
51. Laghmani, K.; Preisig, P.A.; Moe, O.W.; Yanagisawa, M.; Alpern, R.J. Endothelin-1/endothelin-B receptor-mediated increases in NHE3 activity in chronic metabolic acidosis. J. Clin. Invest. 2001, 107, 1563–1569.
52. Chu, T.S.; Peng, Y.; Cano, A.; Yanagisawa, M.; Alpern, R.J. Endothelin(B) receptor activates NHE-3 by a Ca2+-dependent pathway in OKP cells. J. Clin. Invest. 1996, 97, 1454–1462.
53. Herrera, M.; Hong, N.J.; Ortiz, P.A.; Garvin, J.L. Endothelin-1 inhibits thick ascending limb transport via Akt-stimulated nitric oxide production. J. Biol. Chem. 2009, 284, 1454–1460.
54. Plato, C.F.; Pollock, D.M.; Garvin, J.L. Endothelin inhibits thick ascending limb chloride flux via ET(B) receptor-mediated NO release. Am. J. Physiol. Renal Physiol. 2000, 279, F326–F333.
55. Bailly, C. Effect of luminal atrial natriuretic peptide on chloride reabsorption in mouse cortical thick ascending limb: inhibition by endothelin. J. Am. Soc. Nephrol. 2000, 11, 1791–1797.
56. Gerstung, M.; Roth, T.; Dienes, H.P.; Licht, C.; Fries, J.W. Endothelin-1 induces NF-kappaB via two independent pathways in human renal tubular epithelial cells. Am. J. Nephrol. 2007, 27, 294–300.
57. Zeidel, M.L.; Brady, H.R.; Kone, B.C.; Gullans, S.R.; Brenner, B.M. Endothelin, a peptide inhibitor of Na(+)-K(+)-ATPase in intact renaltubular epithelial cells. Am. J. Physiol. 1989, 257, C1101–C1107.
58. Star, R.A.; Nonoguchi, H.; Balaban, R.; Knepper, M.A. Calcium and cyclic adenosine monophosphate as second messengers for vasopressin in the rat inner medullary collecting duct. J. Clin. Invest. 1988, 81, 1879–1888.
59. Tomita, K.; Nonoguchi, H.; Marumo, F. Effects of endothelin on peptide-dependent cyclic adenosine monophosphate accumulation along the nephron segments of the rat. J. Clin. Invest. 1990, 85, 2014–2018.
60. Ahn, D.; Ge, Y.; Stricklett, P.K.; Gill, P.; Taylor, D.; Hughes, A.K.; Yanagisawa, M.; Miller, L.; Nelson, R.D.; Kohan, D.E. Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J. Clin. Invest. 2004, 114, 504–511.
61. Pavlov, T.S.; Chahdi, A.; Ilatovskaya, D.V.; Levchenko, V.; Vandewalle, A.; Pochynyuk, O.; Sorokin, A.; Staruschenko, A. Endothelin-1 inhibits the epithelial Na+ channel through betaPix/14–3-3/Nedd4–2. J. Am. Soc. Nephrol. 2010, 21, 833–843.
62. Schneider, M.P.; Ge, Y.; Pollock, D.M.; Pollock, J.S.; Kohan, D.E. Collecting duct-derived endothelin regulates arterial pressure and Na excretion via nitric oxide. Hypertension 2008, 51, 1605–1610.
63. Stricklett, P.K.; Hughes, A.K.; Kohan, D.E. Endothelin-1 stimulates NO production and inhibits cAMP accumulation in rat inner medullary collecting duct through independent pathways. Am. J. Physiol. Renal Physiol. 2006, 290, F1315–F1319.
64. Ge, Y.; Bagnall, A.; Stricklett, P.K.; Strait, K.; Webb, D.J.; Kotelevtsev, Y.; Kohan, D.E. Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am. J. Physiol. Renal Physiol. 2006, 291, F1274–F1280.
65. Yamauchi, T.; Ohnaka, K.; Takayanagi, R.; Umeda, F.; Nawata, H. Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells. FEBS Lett. 1990, 267, 16–18.
66. Hocher, B.; Thone-Reineke, C.; Rohmeiss, P.; Schmager, F.; Slowinski, T.; Burst, V.; Siegmund, F.; Quertermous, T.; Bauer, C.; Neumayer, H.H.; et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J. Clin. Invest. 1997, 99, 1380–1389.
67. King, A.J.; Brenner, B.M.; Anderson, S. Endothelin: A potent renal and systemic vasoconstrictor peptide. Am. J. Physiol. 1989, 256, F1051–F1058.
68. Kawaguchi, H.; Sawa, H.; Yasuda, H. Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells. J. Mol. Cell. Cardiol. 1990, 22, 839–842.
69. Barton, M.; Shaw, S.; d’Uscio, L.V.; Moreau, P.; Luscher, T.F. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: Role of ETA receptors for endothelin regulation. Biochem. Biophys. Res. Commun. 1997, 238, 861–865.
70. Lenoir, O.; Milon, M.; Virsolvy, A.; Henique, C.; Schmitt, A.; Masse, J.M.; Kotelevtsev, Y.; Yanagisawa, M.; Webb, D.J.; Richard, S.; et al. Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis. J. Am. Soc. Nephrol. 2014, 25, 1050–1062.
71. Morigi, M.; Buelli, S.; Zanchi, C.; Longaretti, L.; Macconi, D.; Benigni, A.; Moioli, D.; Remuzzi, G.; Zoja, C. Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling. Am. J. Pathol. 2006, 169, 1965–1975.
72. Granstam, S.O.; Granstam, E. Endothelin-induced changes in blood flow in STZ-diabetic and non-diabetic rats: Relation to nitric oxide synthase and cyclooxygenase inhibition. J. Physiol. Sci. 2011, 61, 497–505.
73. Tang, L.; Li, H.; Gou, R.; Cheng, G.; Guo, Y.; Fang, Y.; Chen, F. Endothelin-1 mediated high glucose-induced epithelial-mesenchymal transition in renal tubular cells. Diabetes Res. Clin. Pract. 2014, 104, 176–182.
74. Clozel, M.; Breu, V.; Gray, G.A.; Kalina, B.; Loffler, B.M.; Burri, K.; Cassal, J.M.; Hirth, G.; Muller, M.; Neidhart, W.; et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 1994, 270, 228–235.
75. Kelly, D.J.; Skinner, S.L.; Gilbert, R.E.; Cox, A.J.; Cooper, M.E.; Wilkinson-Berka, J.L. Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat. Kidney Int. 2000, 57, 1882–1894.
76. Cosenzi, A.; Bernobich, E.; Trevisan, R.; Milutinovic, N.; Borri, A.; Bellini, G. Nephroprotective effect of bosentan in diabetic rats. J. Cardiovasc. Pharmacol. 2003, 42, 752–756.
77. Ding, S.S.; Qiu, C.; Hess, P.; Xi, J.F.; Zheng, N.; Clozel, M. Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat. J. Cardiovasc. Pharmacol. 2003, 42, 48–54.
78. Chen, J.; Gu, Y.; Lin, F.; Yang, H.; Zhu, W.; Ma, J.; Lin, S. Endothelin receptor antagonist combined with a calcium channel blocker attenuates renal injury in spontaneous hypertensive rats with diabetes. Chin. Med. J. (Engl) 2002, 115, 972–978.
79. Chen, S.; Khan, Z.A.; Cukiernik, M.; Chakrabarti, S. Differential activation of NF-kappa B and AP-1 in increased fibronectin synthesis in target organs of diabetic complications. Am. J. Physiol. Endocrinol. Metab. 2003, 284, E1089–E1097.
80. Hocher, B.; Lun, A.; Priem, F.; Neumayer, H.H.; Raschack, M. Renal endothelin system in diabetes: comparison of angiotensin-converting enzyme inhibition and endothelin-A antagonism. J. Cardiovasc. Pharmacol. 1998, 31, S492–S495.
81. Dhein, S.; Hochreuther, S.; Aus Dem Spring, C.; Bollig, K.; Hufnagel, C.; Raschack, M. Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model. J. Pharmacol. Exp. Ther. 2000, 293, 351–359.
82. Gross, M.L.; Ritz, E.; Schoof, A.; Helmke, B.; Parkman, A.; Tulp, O.; Munter, K.; Amann, K. Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker. Lab. Invest. 2003, 83, 1267–1277.
83. Gross, M.L.; El-Shakmak, A.; Szabo, A.; Koch, A.; Kuhlmann, A.; Munter, K.; Ritz, E.; Amann, K. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 2003, 46, 856–868.
84. Gagliardini, E.; Corna, D.; Zoja, C.; Sangalli, F.; Carrara, F.; Rossi, M.; Conti, S.; Rottoli, D.; Longaretti, L.; Remuzzi, A.; et al. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. Am. J. Physiol. Renal Physiol. 2009, 297, F1448–F1456.
85. Watson, A.M.; Li, J.; Schumacher, C.; de Gasparo, M.; Feng, B.; Thomas, M.C.; Allen, T.J.; Cooper, M.E.; Jandeleit-Dahm, K.A. The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 2010, 53, 192–203.
86. Zoja, C.; Cattaneo, S.; Fiordaliso, F.; Lionetti, V.; Zambelli, V.; Salio, M.; Corna, D.; Pagani, C.; Rottoli, D.; Bisighini, C.; et al. Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes. Am. J. Physiol. Renal Physiol. 2011, 301, F1114–F1123.
87. Opgenorth, T.J.; Adler, A.L.; Calzadilla, S.V.; Chiou, W.J.; Dayton, B.D.; Dixon, D.B.; Gehrke, L.J.; Hernandez, L.; Magnuson, S.R.; Marsh, K.C.; et al. Pharmacological characterization of A-127722: An orally active and highly potent ETA-selective receptor antagonist. J. Pharmacol. Exp. Ther. 1996, 276, 473–481.
88. Saleh, M.A.; Pollock, J.S.; Pollock, D.M. Distinct actions of endothelin A-selective versus combined endothelin A/B receptor antagonists in early diabetic kidney disease. J. Pharmacol. Exp. Ther. 2011, 338, 263–270.
89. Sasser, J.M.; Sullivan, J.C.; Hobbs, J.L.; Yamamoto, T.; Pollock, D.M.; Carmines, P.K.; Pollock, J.S. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J. Am. Soc. Nephrol. 2007, 18, 143–154.
90. Lee, Y.H.; Song, G.G. Meta-analysis of randomized controlled trials of bosentan for treatment of pulmonary arterial hypertension. Korean J. Intern. Med. 2013, 28, 701–707.
91. Dhillon, S. Bosentan: A review of its use in the management of digital ulcers associated with systemic sclerosis. Drugs 2009, 69, 2005–2024.
92. Rafnsson, A.; Bohm, F.; Settergren, M.; Gonon, A.; Brismar, K.; Pernow, J. The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: A randomised trial. Diabetologia 2012, 55, 600–607.
93. Wenzel, R.R.; Littke, T.; Kuranoff, S.; Jurgens, C.; Bruck, H.; Ritz, E.; Philipp, T.; Mitchell, A. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J. Am. Soc. Nephrol. 2009, 20, 655–664.
94. Mann, J.F.; Green, D.; Jamerson, K.; Ruilope, L.M.; Kuranoff, S.J.; Littke, T.; Viberti, G. Avosentan for overt diabetic nephropathy. J. Am. Soc. Nephrol. 2010, 21, 527–535.
95. Kohan, D.E.; Pritchett, Y.; Molitch, M.; Wen, S.; Garimella, T.; Audhya, P.; Andress, D.L. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J. Am. Soc. Nephrol. 2011, 22, 763–772.
96. Andress, D.L.; Coll, B.; Pritchett, Y.; Brennan, J.; Molitch, M.; Kohan, D.E. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD). Life Sci. 2012, 91, 739–742.
97. De Zeeuw, D.; Coll, B.; Andress, D.; Brennan, J.J.; Tang, H.; Houser, M.; Correa-Rotter, R.; Kohan, D.; Lambers Heerspink, H.J.; Makino, H.; et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J. Am. Soc. Nephrol. 2014, 25, 1083–1093.
98. Barst, R.J.; Rich, S.; Widlitz, A.; Horn, E.M.; McLaughlin, V.; McFarlin, J. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: Open-label pilot study. Chest 2002, 121, 1860–1868.
99. Hoeper, M.M.; Olsson, K.M.; Schneider, A.; Golpon, H. Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy. Eur. Respir. J. 2009, 33, 1518–1519.
100. Lee, W.T.; Kirkham, N.; Johnson, M.K.; Lordan, J.L.; Fisher, A.J.; Peacock, A.J. Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension. Eur. Respir. J. 2011, 37, 472–474.
101. Lavelle, A.; Sugrue, R.; Lawler, G.; Mulligan, N.; Kelleher, B.; Murphy, D.M.; Gaine, S.P. Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension. Eur. Respir. J. 2009, 34, 770–771.
102. Galie, N.; Olschewski, H.; Oudiz, R.J.; Torres, F.; Frost, A.; Ghofrani, H.A.; Badesch, D.B.; McGoon, M.D.; McLaughlin, V.V.; Roecker, E.B.; et al. Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008, 117, 3010–3019.
103. McGoon, M.D.; Frost, A.E.; Oudiz, R.J.; Badesch, D.B.; Galie, N.; Olschewski, H.; McLaughlin, V.V.; Gerber, M.J.; Dufton, C.; Despain, D.J.; et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009, 135, 122–129.
104. Tikkanen, I.; Tikkanen, T.; Cao, Z.; Allen, T.J.; Davis, B.J.; Lassila, M.; Casley, D.; Johnston, C.I.; Burrell, L.M.; Cooper, M.E. Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes. J. Hypertens. 2002, 20, 707–714.